Interview at Redeye about new results for the pain project ACD440 directed at neuropathic pain, the projects orphan drug status at the FDA & the outlicensing strategy.
Redeye in discussion with CEO Martin Jönsson och CSO Johan Sandin about the ACD440 result recently presented at the pain conference NeuPSIG , the companies outlicensing policy , and the orphan drug strategy and the possibilities within erytromelalgi.
See the interview here